Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Korean Study Links Weight-Loss Drugs to Higher Depression and Suicidal Thoughts
- 1866 storm rescue recreation part of festivities
- 6 Hidden Gems in Brazil for Retirees Seeking a Serene, Affordable Lifestyle
- ‘Mothers get lost in the shuffle’: The Clancy trial highlights gaps in postpartum mental health care
- Analytic Philosophy Is the Ideology of the Status Quo
- J-16 fighters fly 3,700 miles for China
- Frontier Health launches campaign to support domestic violence shelter
- No new H1N1 strain in India, existing vaccines sufficient, says ICMR
Browsing: Wegovy
The growing popularity of GLP-1 medications such as Ozempic, Wegovy, and Rybelsus has largely been driven by their ability to help people lose weight, improve blood sugar control, and reduce the risk of cardiovascular disease. Now, researchers have uncovered another possible benefit. A new clinical trial suggests that semaglutide, the active ingredient in those medications,…
The scope of use for the anti-obesity drug Wegovy (active ingredient semaglutide) is expanding beyond weight loss to include the prevention of cardiovascular disease, improvement of fatty liver, mental health benefits, and enhanced fertility.
The explosive growth in semaglutide (Ozempic and Wegovy) We use after its FDA approval for chronic weight management in 2021 was accompanied by another trend that drew researchers’ attention: a dramatic increase in calls to poison control centers across the United States
SINGAPORE, July 8, 2026 /PRNewswire/ — Novo Nordisk announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy® (semaglutide) injection, incorporating clinical evidence from the STEP UP trial in adults living with obesity without diabetes. In the trial, which evaluated a higher dose of semaglutide (7.2 mg), up to one in three…
Most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, despite patients achieving substantial weight loss, a study has found
Wegovy® (semaglutide) label updated in Singapore with higher dose supported by STEP UP evidence – PR Newswire APAC
SINGAPORE, July 8, 2026 /PRNewswire/ — Novo Nordisk announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy® (semaglutide) injection, incorporating clinical evidence from the STEP UP trial in adults living with obesity without diabetes. In the trial, which evaluated a higher dose of semaglutide (7.2 mg), up to one in three…
Pharmacies are “bracing themselves” for a surge in patients starting weight loss drugs as the Wegovy pill becomes available
Pharmacies are bracing themselves for a surge in demand after the first weight-loss pill went on sale in the UK today
Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

